Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VIVJOA® (oteseconazole) is an azole antifungal and designed to selectively inhibit fungal CYP51, which is indicated for the treatment of severe vulvovaginal candidiasis (VVC).
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2023
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VIVJOA (oteseconazole) was statistically superior to placebo in preventing recurrence of infection in women with RVVC and noninferior to fluconazole in treating acute VVC in women with RVVC.
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Two global VIOLET Phase 3 studies met primary and key secondary endpoints, with authors concluding VIVJOA (oteseconazole) is highly efficacious in preventing recurrence of VVC through 48 weeks in participants with a history of RVVC.
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VIVJOA™ (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 85% of patients who took a 12-week course of Vivjoa (oteseconazole) completed 96 weeks without a recurrent VVC episode, with an average time of 92 weeks without recurrence.
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Approval of VIVJOA™ marks a significant therapeutic advancement for reducing the incidence of RVVC, a condition with substantial unmet need, in permanently infertile and postmenopausal women.
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Of the 71 VIVJOA (oteseconazole) treated participants in the observational extension study, 85% completed 96 weeks without a recurrent VVC episode, where they had experienced at least three episodes in the year prior to study entry.
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 08, 2022
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oteseconazole (VT-1161) is a novel, oral therapy for RVVC that is designed with the goal of having greater selectivity, fewer side effects and improved efficacy for treatment of recurrent vulvovaginal candidiasis (RVVC).
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The objective of the ultraVIOLET study was to assess the effectiveness of oteseconazole over 50 weeks in the prevention of recurring acute VVC episodes in women with a history of RVVC. The ultraVIOLET study met all primary and secondary endpoints.
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2021
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oteseconazole was designed to be highly selective for its pathogenic target, with fewer side effects and improved efficacy over current treatment options, including fluconazole, the current standard of care for vulvovaginal candidiasis (VVC).
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable